BMRN vs SPGI · P/E 40, rev $1.76B vs P/E 27, rev $15.34B
Biomarin Pharmaceutical Inc (BMRN) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the BMRN and SPGI stock pages for the full models.
Not investment advice.